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Abstract
Background: HIV infection and progression to AIDS is characterized by the depletion of T cells,
which could be due, in part, to apoptosis mediated by the extra-cellular HIV-encoded Tat protein
as a consequence of Tat binding to tubulin. Microtubules are tubulin polymers that are essential for
cell structure and division. Molecules that target microtubules induce apoptosis and are potent anti-
cancer drugs. We studied the effect on tubulin polymerization of three Tat variants: Tat HxB2 and
Tat Eli from patients who are rapid progressors (RP) and Tat Oyi from highly exposed but
persistently seronegative (HEPS) patients. We compared the effect on tubulin polymerization of
these Tat variants and peptides corresponding to different parts of the Tat sequence, with
paclitaxel, an anti-cancer drug that targets microtubules.
Results:  We show that Tat, and specifically, residues 38–72, directly enhance tubulin
polymerization. We demonstrate that Tat could also directly trigger the mitochondrial pathway to
induce T cell apoptosis, as shown in vitro by the release of cytochrome c from isolated
mitochondria.
Conclusions:  These results show that Tat directly acts on microtubule polymerization and
provide insights into the mechanism of T cell apoptosis mediated by extra-cellular Tat.
Introduction
AIDS is due to human immunodeficiency virus (HIV-1)
infection of CD4 T cells and is characterized by the cell
death of HIV-infected lymphocytes and uninfected
bystander cells [1-4]. Recent discoveries have shown that
this could be related to the extra-cellular effects of Tat,
which is a toxic protein secreted early by HIV-infected cells
[5,6]. Tat was first identified as a regulatory protein essen-
tial in the HIV viral cycle due to its ability to dramatically
increase HIV gene expression [7]. The size of Tat varies
and exists in forms between 86 and 101 residues. Yet 101
residues now appear to be the dominant size in the field
[6]. Interest in this protein was raised with the discovery
that Tat was secreted from HIV-infected cells and that it
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could have extra-cellular functions related to AIDS patho-
genesis such as Kaposi's sarcoma [8]. The extra-cellular
roles of Tat are suspected to be the major reason for the
maintenance of HIV-infected cells (or reservoir cells) [5],
and could explain the failure of current antiviral therapies
to eradicate HIV [9]. Tat induces apoptosis in different cell
lines such as macrophages and cytotoxic T-lymphocytes
(CTL) [10], which are essential for the cellular response of
the immune system to eliminate virus-infected cells [6].
Different mechanisms by which Tat induces apoptosis in
T cells were proposed: (i) The up-regulation of Fas ligand
[10]; (ii) The up or down regulation of cellular genes
encoding for cytokines [11], for cell survival factors such
as Bcl-2 [12-14], for superoxide-dismutase [15], and for
p53 [16]; (iii) The inhibition of the expression of manga-
nese-dependant superoxide dismutase [17]; (iv) The acti-
vation of cyclin dependant kinases [18].
Another mechanism was proposed that involves microtu-
bules to induce Tat-mediated apoptosis [19]. We showed
recently, using two short Tat variants of 86 residues, that
Tat is able to form a complex with tubulin [20]. Microtu-
bules are tubulin polymers necessary for the change and
preservation of cellular morphology, intracellular
organelle distribution, chromosome migration during
mitosis, cell differentiation, as well as intracellular trans-
port and signalization [21]. Microtubule damaging agents
(MDAs) are classified in microtubule-stabilizing agents
such as Taxanes and microtubule depolymerizing agents
such as Vinca.alkaloids. The MDAs inhibit microtubule
dynamics in living cells and lead to apoptosis after cell
cycle disturbance [21-24]. They activate the intrinsic mito-
chondrial apoptotic pathway as shown by the mitochon-
drial membrane potential collapse and the opening of the
permeability transition pore [25,26]. The subsequent
release of pro-apoptotic factors, such as cytochrome c,
leads to the caspase cascade activation and thus to apop-
tosis [27]. Moreover, MDAs can also directly affect mito-
chondria, as shown in vitro by the release of cytochrome c
from isolated mitochondria [28].
The aim of this study was to evaluate the consequence of
Tat binding to microtubules and the correlation with the
mitochondria-mediated T cell apoptosis. We used three
Tat variants with sequences from 99 to 101 that have the
size of the main Tat variants found in the field [6]. The
HIV-1 HxB2 and HIV-1 Eli are representative of rapid pro-
gressor (RP) patients in respectively Euro-American
strains [29] and African strains [30]. HIV-1 Oyi strain was
isolated from a highly exposed persistently sero-negative
(HEPS) individual during an epidemiological study in
Gabon [31]. In order to identify the regions of Tat essen-
tial for the interaction with microtubules, we used pep-
tides corresponding to different part of the Tat sequence.
We compared the effect of these Tat variants and Tat pep-
tides with paclitaxel, a well-known anti-cancer drug agent
that strongly increases tubulin polymerization and stabi-
lizes microtubules [32].
Results
Tat acts on tubulin in vitro
The minimal concentration of tubulin (Cr) necessary to
obtain tubulin polymerization without drug was 7 µM in
our buffer conditions [33]. We measured the polymeriza-
tion effect of various concentrations of Tat and paclitaxel
with 15 µM tubulin. We did observe the enhancement of
tubulin into microtubules in the presence of Tat and pacl-
itaxel (Fig. 1A). In comparison with tubulin alone (line
1), the rate of assembly as well as the final extent of assem-
bly was enhanced by Tat. Furthermore, the lag time to
start polymerization is shorter with Tat (lines 2 and 4) as
compared with tubulin alone (line 1). With 4 µM (line 2)
and 8 µM Tat (line 4), turbidity reached a plateau at 0.55
and 1.20 respectively, which corresponds to a 1.7 and 3.7
fold increase compared with the control plateau at 0.32
obtained with tubulin alone (line 1) (Fig. 1A). With
higher concentrations of Tat (16 µM and 20 µM) the tur-
bidity plateaus were superior to 5. The lowest effective
concentration of Tat that induced an increase in polymer-
ization was 0.5 µM (data not shown).
When the temperature of the samples was decreased to
10°C, we observed a complete depolymerization for
tubulin alone (line 1) and tubulin with 4 µM and 8 µM
Tat (lines 2 and 4 respectively). Even at the highest con-
centrations of Tat (16 µM and 20 µM), at 10°C the turbid-
ity decreased to the original values (data not shown). By
contrast, in the same conditions, we did not observe any
depolymerization in the presence of paclitaxel (line 3).
However, full depolymerization in the presence of paclit-
axel was obtained with a longer incubation at 4°C (data
not shown). The reversibility of following an incubation
at 10°C or 4°C strongly suggests that turbidity enhance-
ment is not related to precipitation or aggregation but to
microtubule formation.
We also observed that when Tat concentration is increased
to stoichiometric quantities with tubulin, the turbidity
values increased dramatically to an absorbance greater
than 2.
These values are superior to the absorbance obtained in
the same conditions using the stoichiometric quantity (15
µM) of paclitaxel, which induces effective tubulin polym-
erization. Turbidity is known to be a function of the total
weight concentration of scattering particles only when the
particles have small diameters compared with the wave-
lengths of the incident light [34,35]. Thus, it seemed Tat
would be able to act quantitatively and qualitatively on
tubulin polymerization. In order to address theseRetrovirology 2005, 2:5 http://www.retrovirology.com/content/2/1/5
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possibilities, our first control was to verify the shape of
microtubules formed in the presence of Tat. Examination
with electron microscopy confirmed the formation of
microtubules in the presence of Tat, that were similar in
shape to the controls without Tat (Fig. 1B). However,
microtubules in the presence of Tat and paclitaxel were
slightly packed and shorter than non-treated microtu-
bules. These phenomena were in part responsible for the
variation in turbidity. To determine whether a part of the
enhancement of turbidity was due to an increase in tubu-
lin polymerization, we did evaluate the amount of polym-
erized tubulin on gel after ultra-centrifugation. Results in
figure 1C show that with Tat or paclitaxel the band inten-
sity of pellets (P) are enhanced and the band intensity of
supernatants (S) are decreased compared with the control
tubulin alone. Increasing the concentration of Tat to 8 µM
(Tat 8) and 16 µM (Tat 16) indeed enhanced the propor-
tion of tubulin in the pellets (P) and decreased the pro-
portion of tubulin in the supernatant (S) (Fig. 1C). Thus,
although the enhanced turbidity is due in part to microtu-
bule aggregation, these results show that the increase
expansion in the turbidity plateau is also due to an
increasing amount of microtubules. Interestingly, analysis
of the samples by gel electrophoresis, using a five-fold
amount of the tubulin samples loaded on gels showed
that Tat was only detectable in the pellet fraction (Fig.
1C). To eliminate non-specific binding, we used a glycerol
cushion during the ultra-centrifugation step [33]. This
confirmed that Tat was associated with the microtubules.
We evaluated the ability of different Tat variants to modify
tubulin polymerization. In our conditions, when 15 µM
of tubulin are incubated at 37°C with 8 µM Tat HxB2, Eli
or Oyi, the turbidity plateau values at 350 nm are 1.01,
1.61 and 0.80 respectively (Table 1). These values are
higher than the turbidity value of 0.30 obtained with 15
µM tubulin alone (Table 1). Thus Tat from different HIV
subtypes are able to enhance tubulin polymerization.
However, Tat Eli and Tat HxB2 are more effective in this
enhancement than Tat Oyi (Table 1, column O.D. ratio).
To identify the sequence(s) region(s) implicated in tubu-
lin, peptides overlapping the sequence of Tat HxB2 and
Tat Oyi were synthesized. The sequences of peptides 38–
72 and 73–99 derived from both Eli and Oyi are indicated
in figure 2. Using 8 µM of peptide 38–72 from Eli (line
Pep38–72 ELI) and Oyi (line Pep38–72 OYI) in the pres-
ence of 15 µM tubulin, we obtained a turbidity plateau
value of 1.59 for Eli and 0.78 for Oyi which correspond to
an increased ratio of 5.20 and 2.56 (Table 1). These effects
were comparable with the effect of the entire parental Tat
proteins. Turbidity with the peptide 73–99 derived from
Eli (Pep73–99 ELI) and Oyi (Pep73–101 OYI) were at the
same level as the control, indicating that they were not
active in tubulin polymerization (last lines, Table 1).
Turbidity time course of the in vitro microtubule assembly Figure 1
Turbidity time course of the in vitro microtubule assembly. 
(A) Tubulin in presence of various ligands. Samples with 15 
µM tubulin are maintained at 4°C. After addition of 8 µM Tat 
(line 4), 4 µM Tat (line 2) from HIV-1 HxB2 strain or 15 µM 
paclitaxel (line 3), the assembly reaction was started by 
warming the samples at 37°C (time 0, arrow) and compared 
to tubulin alone (line1). The ∆OD350 nm is measured every 
30 sec. After 30 min the temperature was lowered to 10°C 
(arrow). (B) Electron microscopy of microtubules formed in 
the presence of Tat. Aliquot from samples reaching the 
∆DO350 nm plateau at 37°C were adsorbed on coated 
Formvar films on copper grids. Electron micrographs of 
microtubules formed without Tat (Control) or with indi-
cated concentrations of Tat and paclitaxel are presented with 
4000-fold magnification. Microtubules formed with Tat at 8 
µM are also presented at 40000-fold magnification. (C) Pro-
duction of microtubules in the presence of Tat. Samples of 
15 µM tubulin alone (Control) and with 8 µM Tat (Tat 8), 16 
µM Tat (Tat 16) or 15 µM paclitaxel (Paclitaxel) at the time 
they reach the plateau at 37°C were ultracentrifuged and 
supernatant (S) and pellets (P) were analyzed on SDS-PAGE. 
(Tat 8) × 5 indicates a fivefold increase in the quantity of the 
sample loaded. The mass of tubulin (Tub 55 kDa) and Tat 
(Tat 10 kDa) are indicated.Retrovirology 2005, 2:5 http://www.retrovirology.com/content/2/1/5
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Tat-mediated apoptosis in T-cells correlates with the 
effect on microtubules
Drugs that are able to bind to tubulin and/or microtu-
bules are known to affect the microtubule network organ-
ization and block the cell cycle in mitosis, leading to cell
death. We first evaluated the toxicity of the different Tat
variants on Jurkat lymphocyte cells, using 4'6-diamidino-
2-phenylindole (DAPI) staining. This method allows the
quantification of apoptotic cells by the observation of the
characteristic nuclear fragmentation. After 20 hours treat-
ment, the percentage of apoptotic cells in the presence of
10 µM Tat HxB2 (11 %) and 10 µM Tat Eli (12.5 %) were
higher than those obtained with 10 µM Tat Oyi (3.5 %)
(Fig. 3A). These differences in apoptosis were significant
(p = 0.037) using one-sided ANOVA. The percentages of
apoptotic cells in the presence of 1 µM Tat Oyi were simi-
lar to the control cells (0.1 %) (Fig. 3). The percentages of
apoptotic cells in the presence of 1 µM Tat HxB2 (2.7 %),
1 µM Tat Eli (2 %) and 10 µM Tat Oyi (3.5 %) was weak
and comparable to the basal level of the non-treated con-
trol cells (Fig. 3A). Thus, at 10 µM Tat HxB2 and Tat Eli
induced apoptosis inversely to 10 µM Tat Oyi. These
results indicate that Tat-mediated apoptosis in T-cells
could be correlate with the effect on microtubules since
the differences in toxicity between the different Tat vari-
ants correspond to the same differences in tubulin polym-
erization. These differences were also observed using
trypan blue exclusion (data not shown). Tat toxicity was
then confirmed by flow cytometry analysis after propid-
ium iodide (Pi) staining. Figure 3B shows that 1 µM and
10 µM Tat HxB2 induces 13% and 27% apoptosis respec-
tively, revealed by the proportion of cells with hypodip-
loid DNA content (Fig. 3B, H values). A high proportion
of apoptotic cells (31 %) was also obtained with 10 µM of
Tat Eli. Furthermore, the percentage of hypodiploid cells
obtained with 10 µM Tat Oyi is low (10.4 %) and is the
same as the control without Tat (9.9 %).
Tat does not affect microtubule network organization nor 
cell cycle progression
Paclitaxel stabilizes the microtubule network by inducing
the formation of pseudoasters in mitotic cells and the for-
mation of bundles, structures that correspond to strongly
associated microtubules, in interphasic cells [21]. Consid-
ering that Tat increased microtubule polymerization, we
investigated if Tat was able to induce bundle formation or
another disturbance in the microtubule network organi-
zation in the treated cells. The effects of Tat and paclitaxel
cytotoxic concentrations (10 µM and 1 µM respectively)
were evaluated by immunofluorescence microscopy on
Table 1: Enhancement of tubulin polymerization by different Tat and derived peptides
Compounds Concentration ∆OD350 nm ∆OD ratio
none 0.31 1
Tat HxB2 8 µM 1.01 3.31
Tat OYI 8 µM 0.80 2.63
Tat ELI 8 µM 1.61 5.27
Paclitaxel 15 µM 0.55 1.79
Pep38–72 OYI 8 µM 0.78 2.56
Pep38–72 ELI 8 µM 1.59 5.20
Pep73–101 OYI 8 µM 0.31 1.01
Pep73–99 ELI 8 µM0 . 3 0 1
15 µM tubulin is incubated at 37°C in buffer, the increase of ∆OD350 nm is followed and the value of the plateau is indicated in the column ∆OD350 
nm. Lane 1 is the control with tubulin alone (none), lanes 2–4 are Tat variants, lane 5 is the paclitaxel control, lanes 6–9 are the Tat peptides. The 
∆OD350 nm ratio is the value that the ∆OD350 nm plateau reaches in presence of the indicated product divided by the value of the ∆OD350 nm plateau 
reached with tubulin alone.
Sequences of HIV-1 Tat strains Figure 2
Sequences of HIV-1 Tat strains. These three Tat variants and the peptides were obtained by solid phase synthesis with a pro-
cedure previously described [43, 50]. Sequences correspond to the viral strains HIV-1 Eli [30], HIV-1 HxB2 [29] and HIV-1 Oyi 
[30].Retrovirology 2005, 2:5 http://www.retrovirology.com/content/2/1/5
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Effect of different Tat variants on cell cycle progression, apoptosis and microtubule network in lymphocytes Figure 3
Effect of different Tat variants on cell cycle progression, apoptosis and microtubule network in lymphocytes. (A) Table showing 
data from fluorescence microscopy after 20 hours treatment with indicated concentration of Tat or paclitaxel. Percentage of 
apoptotic cells are determined after DAPI staining and the differences in apoptosis between treated and untreated cells used as 
control obtained in three independent experiments are presented. (B) Jurkat cells were treated with indicated concentrations 
of paclitaxel and various Tat or were untreated (control). After 20 hours, cells were stained with PI and analysed by flow 
cytometry. Percentage of cells in G2/M (G2 / M) or apoptotic cells (H) with hypodiploid DNA are indicated in the upper cor-
ner of each cell (C) Jurkat cells were treated with 10 µM Tat Eli or 1 µM paclitaxel and processed for immunofluorescence 
labeling with anti-alpha tubulin antibody as described in materials and methods. Control corresponds to untreated cells.Retrovirology 2005, 2:5 http://www.retrovirology.com/content/2/1/5
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Jurkat cells. After 6 hours treatment with paclitaxel, strong
modifications of the microtubule network (that form
bundles) were observed (Fig. 3C). However, in the pres-
ence of 10 µM Tat, we did not observe bundles or any
other modification of the microtubule network.
By disturbing microtubule functions, MDAs generally
lead to a mitotic block of treated cells. Although study
have implicated the transactivation effect of Tat on cyclin
and other gene implicated in cell cycle progression, we
examined if Tat induced a mitotic block that could be due
in part to the tubulin polymerization of Tat. Following
treatment, the percentage of cells in various phases was
obtained by flow cytometry analysis after propidium
iodide incorporation. After 20 hours treatment, 1 µM
paclitaxel blocks almost 50 % of the cells in the G2/M
phase (Fig. 3B, G2/M values). This strong blockage in G2/
M with paclitaxel attests that we were in the appropriate
time conditions to evaluate the effects of Tat on cell cycle
regulation in these Jurkat cells. A longer incubation time
(i.e. 48 h) in the presence of paclitaxel leads to 90 % of cell
death (data not shown). After 20 hours treatment, the per-
centage of the G2/M cells in the presence of 1 µM Tat
HxB2 or 10 µM Tat Oyi were 28 % and 32 % respectively
and similar to the 33 % observed in the untreated cells
(Fig. 3B). In the presence of 10 µM Tat HxB2 or 10 µM Tat
Eli the percentage of G2/M cells (22 % and 24 % respec-
tively), were lower than the control cells (33 %). This
decrease of the G2/M is not correlated with an increase in
G1, and seems to be related to the strong cell death (30 %)
rather than to a specific block in another cell cycle phase.
In parallel, DAPI results confirmed that the percentages of
metaphasic cells were similar between untreated cells and
Tat-treated cells (1 %), in contrast to paclitaxel-treated
cells that were blocked in metaphase (50 %). Thus, con-
trary to paclitaxel, the different Tat variants did not lead to
a G2/M block before inducing apoptosis.
Tat induces the release of cytochrome c from isolated 
mitochondria
MDAs induce apoptosis through the mitochondrial apop-
tosis pathway. Our previous work on paclitaxel showed
that this agent is able to induce cytochrome c release from
purified mitochondria [28]. To investigate whether Tat
could directly target mitochondria, we isolated these
organelles and incubated them with growing concentra-
tions of Tat Eli (0.2 µM, 2 µM and 10 µM). Using Western
Blot analysis, we detected cytochrome c in the supernatant
of mitochondria incubated with Tat Eli (Fig. 4A, Cyt c).
Enhanced amounts of cytochome c were observed with 2
µM and 10 µM Tat Eli (lane T10 and T2) whereas the level
of cytochrome c with 0.2 µM of Tat Eli (lane T0.2) was
comparable to the untreated mitochondria (lane T-). In
parallel, cytochrome c  levels decreased slightly in
mitochondria treated with Tat, as revealed by Western
Blot of the pellets (Fig. 4B, Cyt c). Levels of VDAC, mito-
chondrial outer membrane porin, were systematically
measured to ensure that equal amounts of mitochondria
were present in the pellets (Fig. 4B, VDAC), and that no
mitochondria remained in the supernatants (Fig. 4A,
VDAC).
Tat induces cytochrome c release from isolated  mitochondria Figure 4
Tat induces cytochrome c release from isolated mitochon-
dria. After 2 hour treatment with 10 µM (P10) of peptide 
73–99 or 0.2 µM (T0.2), 2 µM (T2) and 10 µM (T10) of Tat 
Eli or without peptide (T-), samples were centrifuged and 
supernatants and pellets were separated. (A). Western blots 
of the supernatant with antibodies against cytochrome c (Cyt 
C) and with antibodies against VDAC. (B) Western blots of 
Mitochondria Pellets. Data are representative of four inde-
pendent experiments.Retrovirology 2005, 2:5 http://www.retrovirology.com/content/2/1/5
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Discussion
Our in vitro study clearly shows that Tat directly interacts
with microtubules and is able to enhance their formation.
Turbidimetry tests showed that Tat strongly enhanced
pure tubulin polymerization. The Tat concentration
inducing tubulin polymerization is higher compared to
the concentration of Tat in the plasma and it is possible
that Tat concentration increases in the cell due to an active
uptake similar to what is observed with paclitaxel. Fur-
thermore, it is also possible that Tat concentration in the
plasma is higher nearby HIV infected cells. We found that
Tat acts qualitatively on microtubules making them
shorter, such as paclitaxel, and also induces microtubule
packing. These effects on microtubule formation are more
pronounced than with paclitaxel as observed by turbidim-
etry and electron microscopy. The high effect of Tat on the
self-association of tubulin is of interest for studies on the
mechanism of microtubule formation and could be used
in the design of new agents targeting microtubules.
We also showed that the full-length Tat protein is not nec-
essary to obtain tubulin polymerization enhancement as
peptides derived from its central region harbored the
same properties as the full-length protein. These peptides
contain the glutamine-rich region of Tat and confirms that
the glutamine-rich region of Tat is involved in Tat medi-
ated apoptosis [20]. It also contains the basic region
(sequence 49–60) that is essential for Tat to cross mem-
branes [36] and the adjacent region (sequence 38–48)
that has been previously shown to be involved in the Tat-
tubulin interaction [19]. In this study, we demonstrate
that the N-terminus and the C-terminus of Tat are not nec-
essary for the interaction with tubulin.
We showed that the more toxic Tat variants were also
those that were more active in the polymerization of tubu-
lin in vitro, suggesting that the toxicity of extra-cellular Tat
is mediated by a mechanism involving microtubules.
MDAs such as paclitaxel, which affect tubulin polymeriza-
tion, generally disturb the microtubule network functions
and inhibit cell proliferation. Contrary to paclitaxel, in the
presence of high concentrations of Tat, we did not observe
cell cycle arrest in G2/M. Moreover, by immunofluores-
cence microscopy, we did not detect any early modifica-
tion of the microtubule network organization, even with
high Tat concentrations. MDAs are able to induce apopto-
sis at lower doses than those required to induce bundles
[21]. Interestingly, low concentrations of MDAs can sup-
press microtubule dynamics and disturb their functions,
without modifying microtubule network morphology
[21,27,37]. Thus, low cytoplasmic concentrations of Tat
could modulate microtubule dynamics participating in
the apoptotic signaling pathway induction in lym-
phocytes. The effect of Tat on microtubule dynamic needs
to take in account that Tat could also modify the activity
of proteins acting on microtubule dynamic such as LIS1
[38].
We hypothesize that Tat is able to induce the release of
pro-apoptotic factors from mitochondria as we have pre-
viously shown this property for microtubule damaging
agents [28]. We show here for the first time that Tat is able
to directly affect isolated mitochondria and trigger cyto-
chrome c release, a key event in the mitochondrial apop-
totic pathway activation. This result is in agreement with
those from Macho et al. that show that, in lymphocyte cul-
tures under low serum conditions, Tat accumulates at the
mitochondria. Moreover, this localization correlated with
disruption of the mitochondrial membrane potential
[39], a process that leads to the release of pro-apoptotic
factors such as cytochrome c. Thus, we show in this study
that secreted Tat can both act on tubulin polymerization
and on the mitochondria in vitro.
Interestingly, although our study involves only three Tat
variants, our results show that, in comparison with Tat
Oyi, the Tat HxB2 and Tat Eli derived from RP are more
potent in tubulin polymerization and apoptosis induc-
tion in T-cell. This open the possibility that these proper-
ties of Tat could be associated with more severe disease
phenotype.
Apoptosis of bystander cells has been demonstrated to be
very important in AIDS [40] and the rate of lymphocyte
apoptosis has been correlated with progression rates [41].
It now appears that extra-cellular Tat secreted from HIV-
infected cells is involved in the apoptosis of non-infected
T cells. The elucidation of the mechanism responsible for
Tat-mediated inhibition of the immune response there-
fore should have a tremendous impact for AIDS therapy.
Methods
Protein synthesis, Purification and Biochemical 
Characterization
Tat variants and their derived peptides were synthesized
with an ABI 433A peptide synthesizer (Perkin Elmer,
Applied Biosystem Inc.) with FASTMoc chemistry accord-
ing to the method of Barany and Merrifield [42] on 4-
hydroxymethyl-phenoxy-methyl-copolystyrene-1% divi-
nylbenzene preloaded resin (HMP; 0.50–0.65 mmol; Per-
kin Elmer, Applied Biosystem Inc., Foster City, CA), as
previously described [43,44]. Purity and integrity of
proteins were confirmed by amino acid composition
(6300 Beckman analyzer), partial sequence analyses
(473A Protein Sequencer, Applied Biosystem) and by
MALDI-TOF mass spectrometry (Perspective Biosystems,
Voyager DE-RP).Retrovirology 2005, 2:5 http://www.retrovirology.com/content/2/1/5
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Purified Lamb Brain Tubulin
Lamb brain tubulin was purified by ammonium sulfate
fractionation and ion-exchange chromatography, stored
in liquid nitrogen and prepared for use as described
[45,46]. During this purification particular caution was
taken to remove microtubule-associated proteins (MAPs).
Protein concentrations were determined spectrophoto-
metrically with a Perkin-Elmer spectrophotometer
Lambda 800. Tubulin extinction coefficient is ε275 nm =
1.07 L·g-1·cm-1 in 0.5% SDS in neutral aqueous buffer or
ε275 nm = 1.09 L·g-1·cm-1 in 6 M guanidine hydrochloride.
Tubulin polymerization
In vitro studies have been derived from experiments that
show that the variation of temperature permits the
disassembly/reassembly cycles of tubulin in the presence
of GTP and Mg2+ [47,48]. Microtubule assembly was per-
formed in 20 mM sodium phosphate buffer, 1 mM EGTA,
10 mM MgCl2, and 3.4 M glycerol, pH 6.5. The various
concentrations of Tat or paclitaxel were mixed with tubu-
lin at 4°C. The reaction was started by warming the sam-
ples to 37°C in a 0.2 × 1 cm cells, and the mass of polymer
formed was monitored by turbidimetry at 350 nm using a
Beckman DU7400 spectrophotometer thermostated.
Depolymerization occurs when the temperature is low-
ered to 10°C. The data showed in fig 1a were representa-
tive of three independent experiments. ∆OD350 nm values
correspond to values without the buffer. The microtubule
mass was determined by centrifugation assay. Samples
were taken at the turbidity plateau at 37°C. They were
ultra-centrifuged at 50,000 rpm for 15 min at 37°C using
fixed angle rotor TLA 100.2 in a TL100 Beckman appara-
tus. In these conditions, microtubules precipitate in the
pellet and non- polymerised tubulin remains in the super-
natant. Pellet and supernatant were loaded separately on
10 % acrylamide SDS-PAGE, colored with Coomassie
blue after migration (Fig. 1C).
Electron microscopy
Small aliquots of tubulin associated with Tat were
adsorbed on coated Formvar films on copper grids. They
were negatively stained for 1 min in 2 % uranyl acetate
and observed with a Jeol 1220 electron microscope.
Cell Culture
The lymhoblastoid Jurkat cell line was cultured in RPMI
1640 supplemented with 2 mM ultraglutamine
(BioWhittaker, Verviers, Belgium), penicillin (100 U/ml),
streptomycin (100 µg/ml), and 10 % heat-inactivated
fetal calf serum (BioWhittaker, Verviers, Belgium).
Human neuroblastoma SK-N-SH cells were routinely
maintained at 37°C and 5 % CO2, in standard culture
RPMI-1640 medium (BioWhittaker, Verviers, Belgium)
containing 10 % fetal bovine serum (BioWhittaker), 2
mM glutamine (BioWhittaker, Verviers, Belgium), 1 %
penicillin and streptomycin (BioWhittaker, Verviers, Bel-
gium). Exponentially growing cells (105 cells/ml) were
seeded 3 days before paclitaxel or Tat treatment.
Drugs and Antibodies
Stock solution of paclitaxel (Sigma) was prepared in
DMSO. The final concentration of DMSO used in cell cul-
ture was less than 0.05 %. For Western blotting, anti-
VDAC antibody (anti-porin, 31 HL France Biochem, Meu-
don, France) was used at 1/500 and anti- cytochrome c
antibody (7 h82C12; PharMingen, San Diego, CA) was
used at 1/1000. Secondary antibody was goat antimouse
monoclonal antibody conjugated with peroxidase (Jack-
son ImmunoResearch Laboratories, USA). The antibodies
used for immunofluorescence microscopy were anti-α-
tubulin (clone DM1A Sigma, Saint Louis, USA) and FITC
mouse anti-goat IgG (Jackson ImmunoResearch Labora-
tories, USA).
Cell death analysis
Jurkat cells at a concentration of 5 × 105 cells/ml were
incubated in the absence or presence of Tat or paclitaxel at
different concentrations (see Fig. 3). After 20 hours incu-
bation at 37°C, they were counted under optic micro-
scope and cell death was estimated by trypan blue
exclusion. Cells were then permeabilized with glacial
alcohol, stained with propidium iodide and DNA content
was measured by flow cytometry (Facs Calibur, Becton
Dickinson, Mississauga, Canada). Cytogram analysis was
performed with Cell Quest Pro® software (Becton Dickin-
son, Mississauga, Canada). The proportion of hypodip-
loid cells was used as an estimate of apoptosis. Cell death
was further analysed using fluorescence microscopy of
cells stained with DAPI. 5 × 105. Jurkat cells/ml were incu-
bated at 37°C for 20 hours with various Tat or paclitaxel
in Lab-Tek chamber slides. (Nalge Nunc International.,
USA). After centrifugation for 10 min at 3500 rpm, spin
cells were fixed with 3.7 % formaldehyde, permeabilized
with 0.1 % saponin and treated with PBS containing 10
µg/ml 4'6-diamidino-2-phenylindole (DAPI) (Sigma).
The morphology of the cell nuclei was observed with a flu-
orescence microscope using an excitation wavelength of
350 nm. Nuclei were considered to have the normal phe-
notype when glowing bright and homogenously. Specific
well drawn line up chromosome were seen in equatorial
plates for cells in metaphase. Apoptotic nuclei were iden-
tified by the condensed chromatin gathering at the
periphery of the nuclear membrane or a total fragmented
morphology of nuclear bodies. Cells were counted and
the percentage of normal., mitotic and apoptotic nuclei
determined. Data indicated in the figure 3 are representa-
tive of three independent experiments. The apoptosis data
obtained from the three independent experiments in the
presence of paclitaxel and various Tat were comparedRetrovirology 2005, 2:5 http://www.retrovirology.com/content/2/1/5
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using one-sided ANOVA following baseline subtraction
using the values of untreated control cells.
Indirect immunofluorescence staining of alpha-tubulin
106 Jurkat cells/ml were treated for 6 hours with 10 µM Tat
HxB2 or 1 µM paclitaxel and were processed for tubulin
indirect immunofluorescence staining as previously
described [49]. After incubation with paclitaxel or Tat for
6 hr in lab-tek chamber slides (Nalge Nunc International,
USA), the cells were centrifuged for 10 min at 3500 rpm.
They were then fixed with 3.7 % formaldehyde and per-
meabilised with 0.1% saponin. Immunofluorescence
microscopy of the microtubule network was performed
using anti- α-tubulin antibody (Amersham, USA) and an
FITC-conjugated secondary antibody (Jackson Immu-
noResearch Laboratories, USA).
Effect on mitochondria
Mitochondria were isolated by cell fractionation from the
neuroblastoma SK-N-SH cell line as previously described
[28]. 9 × 107 cells were suspended in a sucrose buffer (250
mM sucrose, 1 mM dithiothreitol, 10 mM KCl, 1 mM
EDTA, 1 mM EGTA, 1.5 mM MgCl2, phenylmethylsulfo-
nyl fluoride, protease inhibitors, 20 mM Hepes, pH 7.4)
at 4°C, homogenized with 50 strokes in a glass homoge-
nizer (Kimble Kontes, Vineland, NJ), and centrifuged
twice at 800 g for 10 min. The supernatants were then cen-
trifuged at 15,000 g for 10 min at 4°C. Mitochondrial pel-
lets were immediately washed three times in the sucrose
buffer. Isolated mitochondria were aliquoted and incu-
bated for 2 hr at 37°C with various Tat concentrations.
After centrifugation (15,000 g for 10 min at 4°C), pellets
and supernatants were carefully separated. Mitochondrial
pellets were lysed in lysis buffer (62.5 mM Tris.HCl; pH
6.8, 0.5% SDS, 5% mercaptoethanol, 10% glycerol) and
loaded in parallel with the supernatants on a reducing 15
% SDS-PAGE gel. The gel was processed for immunoblot-
ting and revealed using antibodies against VDAC and
cytochrome c. Anti-VDAC antibody (Calbiochem, USA)
was used to ensure that equal amounts of mitochondrial
proteins were loaded on the gels and that no mitochon-
dria or lyzed mitochondria were present in the superna-
tant. Secondary antibodies were added and visualization
was carried out using an enhanced chemiluminescence
detection kit (ECL, Amersham, Aylesbury, United King-
dom). The results presented are representative of four
independent experiments.
List of abbreviations
HIV, human immunodeficiency virus
MDA, microtubule damaging agent
VDAC, voltage-dependent anion selective channel.
Competing interest
The author(s) declare that they have no competing
interests.
Authors' contributions
JdM carried out most of the experimental work, per-
formed the experimental design and drafted the manu-
script. MC performed part of the cell, mitochondrial and
immunofluorescence study directed by DB. PB performed
tubulin purification, part of tubulin experiments on
polymerization, quantification of microtubules and elec-
tron microscopy directed by VP. GRC, SL, SO, DE and JW
synthezised the peptides and characterized them bio-
chemically and biophysically. CP performed FACS stud-
ies. EPL participated in the design of the study, the
redaction of the manuscript and funded the studies.
Acknowledgements
This work was supported by Agence Nationale pour la Valorisation de la 
Recherche (ANVAR), Conseil régional Provence Alpes Côtes-d'Azur, Con-
seil Général des Bouches-du-Rhones, Ville de Marseille, Association Faire 
Face au SIDA, Centre National pour la Recherche Scientifique (CNRS) and 
the Université d'Aix-Marseille. We thank Eddy Paquier for his help. We 
thank Alain Renaud for technical assistance. SO and JW have scholarships 
from the Conseil Régional Provence Alpes Côtes-d'Azur and SynProsis. GC 
has a scholarship from the Entente Cordiale program between the UK and 
France.
References
1. Weiss RA: How does HIV cause AIDS?  Science 1993,
260:1273-1279.
2. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz
M: Rapid turnover of plasma virions and CD4 lymphocytes in
HIV-1 infection. Nature 1995, 373:123-126.
3. Ameisen JC, Estaquier J, Idziorek T, De Bels F: Programmed cell
death and AIDS pathogenesis: significance and potential
mechanisms. Curr Top Microbiol Immunol 1995, 200:195-211.
4. Finkel TH, Tudor-Williams G, Banda NK, Cotton MF, Curiel T,
Monks C, Baba TW, Ruprecht RM, Kupfer A: Apoptosis occurs
predominantly in bystander cells and not in productively
infected cells of HIV- and SIV-infected lymph nodes. Nat Med
1995, 1:129-134.
5. Gallo RC: Tat as one key to HIV-induced immune pathogen-
esis and Tat (correction of Pat) toxoid as an important com-
ponent of a vaccine. Proc Nat Acad Sci USA 1999, 96:8324-8326.
6. Jeang KT, Xiao H, Rich EA: Multifaceted activities of the HIV-1
transactivator of transcription, Tat.  J Biol Chem 1999,
274:28837-28840.
7. Fisher A, Feinberg M, Josephs S, Harper M, Marselle L, Reyes G,
Gonda M, Aldovini A, Debouk C, Gallo RC, et al.: The trans-activa-
tor gene of HTLV-III is essential for virus replication. Nature
1986, 320:267-271.
8. Ensoli B, Barillari G, Salahuddin SZ, Gallo RC, Wong-Staal F: Tat pro-
tein of HIV-1 stimulates growth of cells derived from
Kaposi's sarcoma lesions of AIDS patients.  Nature 1990,
345:84-86.
9. Ramratnam B, Mittler JE, Zhang L, Boden D, Hurley A, Fang F, Macken
CA, Perelson AS, Markowitz M, Ho DD: The decay of the latent
reservoir of replication-competent HIV-1 is inversely corre-
lated with the extent of residual viral replication during pro-
longed anti-retroviral therapy. Nat Med 2000, 1:82-85.
10. Westendorp MO, Frank R, Ochsenbauer C, Stricker K, Dhein J, Wal-
czak H, Debatin KM, Krammer PH: Sensitization of T cells to
CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature
1995, 375:497-500.Retrovirology 2005, 2:5 http://www.retrovirology.com/content/2/1/5
Page 10 of 11
(page number not for citation purposes)
11. Westendorp MO, Li-Weber M, Frank RW, Krammer PH: Human
immunodeficiency virus type 1 Tat upregulates interleukin-
2 secretion in activated T cells. J Virol 1994, 68:4177-4185.
12. Zauli G, Gibellini D, Caputo A, Bassini A, Negrini M, Monne M, Maz-
zoni M, Capitani S: The human immunodeficiency virus type-1
Tat protein upregulates Bcl-2 gene expression in Jurkat T-
cell lines and primary peripheral blood mononuclear cells.
Blood 1995, 86:3823-3834.
13. Sastry KJ, Marin MC, Nehete PN, McConnell K, el-Naggar AK,
McDonnell TJ: Expression of human immunodeficiency virus
type I tat results in down-regulation of bcl-2 and induction of
apoptosis in hematopoietic cells. Oncogene 1996, 13:487-493.
14. Wang Z, Morris GF, Reed JC, Kelly GD, Morris CB: Activation of
Bcl-2 promoter-directed gene expression by the human
immunodeficiency virus type-1 Tat protein.  Virology 1999,
257:502-510.
15. Flores SC, Marecki JC, Harper KP, Bose SK, Nelson SK, McCord JM:
Tat protein of human immunodeficiency virus type 1
represses expression of manganese superoxide dismutase in
HeLa cells. Proc Natl Acad Sci USA 1993, 90:7632-7636.
16. Li CJ, Wang C, Friedman DJ, Pardee AB: Reciprocal modulations
between p53 and Tat of human immunodeficiency virus type
1. Proc Natl Acad Sci USA 1995, 92:5461-5464.
17. Westendorp MO, Shatrov VA, Schulze-Osthoff K, Frank R, Kraft M,
Los M, Krammer PH, Droge W, Lehmann V: HIV-1 Tat potenti-
ates TNF-induced NF-kappa B activation and cytotoxicity by
altering the cellular redox state. EMBO J 1995, 14:546-554.
18. Li CJ, Friedman DJ, Wang C, Metelev V, Pardee AB: Induction of
apoptosis in uninfected lymphocytes by HIV-1 Tat protein.
Science 1995, 268:429-431.
19. Chen D, Wang M, Zhou S, Zhou Q: HIV-1 Tat targets microtu-
bules to induce apoptosis, a process promoted by the pro-
apoptotic Bcl-2 relative Bim. EMBO J 2002, 21:6801-6810.
20. Campbell GR, Pasquier E, Watkins J, Bourgarel-Rey V, Peyrot V,
Esquieu D, Barbier P, de Mareuil J, Braguer D, Kaleebu P, Yirrell DL,
Loret EP: The Glutamine-Rich Region of HIV-1 Tat Protein
Involved in T-Cell Apoptosis. J Biol Chem 2004, 279:48197-48204.
21. Jordan MA, Wilson L: Microtubules as a target for anticancer
drugs. Nat Rev Cancer 2004, 4:253-265.
22. Yvon AM, Wadsworth P, Jordan MA: Taxol suppresses dynamics
of individual microtubules in living human tumor cells. Mol
Biol Cell 1999, 10:947-959.
23. Goncalves A, Braguer D, Kamath K, Martello L, Briand C, Horwitz S,
Wilson L, Jordan MA: Resistance to Taxol in lung cancer cells
associated with increased microtubule dynamics.  Proc Natl
Acad Sci USA 2001, 98:11737-11742.
24. Honoré S, Kamath K, Braguer D, Horwitz SB, Wilson L, Briand C, Jor-
dan MA: Synergistic suppression of microtubule dynamics by
discodermolide and paclitaxel in non-small cell lung carci-
noma cells. Cancer Res 2004, 64:4957-4964.
25. Goncalves A, Braguer D, Carles G, Andre N, Prevot C, Briand C:
Caspase-8 activation independent of CD95/CD95-L interac-
tion during paclitaxel-induced apoptosis in human colon can-
cer cells (HT29-D4). Biochem Pharmacol 2000, 60:1579-1584.
26. Andre N, Carre M, Brasseur G, Pourroy B, Kovacic H, Briand C, Bra-
guer D: Paclitaxel targets mitochondria upstream of caspase
activation in intact human neuroblastoma cells.  FEBS Lett
2002, 532:256-260.
27. Pourroy B, Carre M, Honore S, Bourgarel-Rey V, Kruczynski A, Bri-
and C, Braguer D: Low Concentrations of Vinflunine Induce
Apoptosis in Human SK-N-SH Neuroblastoma Cells through
a Postmitotic G1 Arrest and a Mitochondrial Pathway. Mol
Pharmacol 2004, 66:580-591.
28. Andre N, Braguer D, Brasseur G, Goncalves A, Lemesle-Meunier D,
Guise S, Jordan MA, Briand C: Paclitaxel induces release of cyto-
chrome c from mitochondria isolated from human neurob-
lastoma cells. Cancer Res 2000, 60:5349-5353.
29. Ratner L, Haseltine W, Patarca R, Livak KJ, Starcich B, Josephs SF,
Doran ER, Rafalski JA, Whitehorn EA, Baumeister K, Ivanoff L, Pette-
way SR, Pearson ML, Lautenberger JA, Papas TS, Ghrayeb J, Chang
NT, Gallo RC, Wongstaal F: Complete nucleotide sequence of
the AIDS virus, HTLV-III. Nature 1985, 313:277-284.
30. Alizon M, Wain-Hobson S, Montagnier L, Sonigo P: Genetic varia-
bility of the AIDS virus: nucleotide sequence analysis of two
isolates from African patients. Cell 1986, 46:63-74.
31. Huet T, Dazza MC, Brun-Vezinet F, Roelants GE, Wain-Hobson S: A
highly defective HIV-1 strain isolated from a healthy
Gabonese individual presenting an atypical western blot.
AIDS 1989, 3:707-715.
32. Parness J, Horwitz SB: Taxol binds to polymerized tubulin in
vitro. J Cell Biol 1981, 91:479-487.
33. Devred F, Douillard S, Briand C, Peyrot V: First tau repeat domain
binding to growing and taxol-stabilized microtubules, and
serine 262 residue phosphorylation.  FEBS Lett 2002,
523:247-251.
34. Berne BJ: Interpretation of the light scattering from long rods.
J Mol Biol 1974, 89:755-758.
35. Gaskin F: Techniques for the study of microtubule assembly in
vitro. Methods Enzymol 1982, 85:433-439.
36. Vives E, Brodin P, Lebleu B: A truncated HIV-1 Tat protein basic
domain rapidly translocates through the plasma membrane
and accumulates in the cell nucleus.  J Biol Chem 1997,
272:16010-16017.
37. Giannakakou P, Nakano M, Nicolaou KC, O'Brate A, Yu J, Blagoskl-
onny MV, Greber UF, Fojo T: Enhanced microtubule-dependent
trafficking and p53 nuclear accumulation by suppression of
microtubule dynamics.  Proc Natl Acad Sci USA 2002,
99:10855-10860.
38. Epie N, Ammosova T, Sapir T, Voloshin Y, Lane WS, Turner W,
Reiner O, Nekhai S: HIV-1 Tat interacts with LIS1 protein. Ret-
rovirology 2005, 2:6.
39. Macho A, Calzado MA, Jimenez-Reina L, Ceballos E, Leon J, Munoz E:
Susceptibility of HIV-1-TAT transfected cells to undergo
apoptosis. Biochemical mechanisms.  Oncogene 1999,
18:7543-7551.
40. Finkel TH, Tudor-Williams G, Banda NK, Cotton MF, Curiel T,
Monks C, Baba TW, Ruprecht RM, Kupfer A: Apoptosis occurs
predominantly in bystander cells and not in productively
infected cells of HIV- and SIV-infected lymph nodes. Nat Med
1995, 1:129-134.
41. Moretti S, Marcellini S, Boschini A, Famularo G, Santini G, Alesse E,
Steinberg SM, Cifone MG, Kroemer G, De Simone C: Apoptosis
and apoptosis-associated perturbations of peripheral blood
lymphocytes during HIV infection: comparison between
AIDS patients and asymptomatic long-term non-
progressors. Clin Exp Immunol 2000, 122:364-373.
42. Barany G, Merrifield RB: The Peptide. In Solid phase peptide synthesis
Volume 2. Edited by: Gross E, Meinhofer J. New York: Academic
Press; 1980:1-284. 
43. Peloponese JM, Collette Y, Gregoire C, Bailly C, Campese D, Meurs
EF, Olive D, Loret EP: Full peptide synthesis, purification, and
characterization of six Tat variants. Differences observed
between HIV-1 isolates from Africa and other continents. J
Biol Chem 1999, 274:11473-11478.
44. Opi S, Peloponese JM Jr, Esquieu D, Watkins J, Campbell G, de
Mareuil J, Jeang KT, Yirrell DL, Kaleebu P, Loret EP: Full-length
HIV-1 Tat protein necessary for a vaccine.  Vaccine 2004,
22:3105-3111.
45. Andreu JM, Gorbunoff MJ, Medrano FJ, Rossi M, Timasheff SN: Mech-
anism of colchicine binding to tubulin. Tolerance of substitu-
ents in ring C' of biphenyl analogues.  Biochemistry 1991,
30:3777-3786.
46. Leynadier D, Peyrot V, Sarrazin M, Briand C, Andreu JM, Rener GA,
Temple C Jr: Tubulin binding of two 1-deaza-7,8-dihydropteri-
dines with different biological properties: enantiomers NSC
613862 (S)-(-) and NSC 613863 (R)-(+).  Biochemistry 1993,
32:10675-10682.
47. Shelanski ML, Gaskin F, Cantor CR: Microtubule assembly in the
absence of added nucleotides.  Proc Natl Acad Sci USA 1973,
70:765-768.
48. Peyrot V, Leynadier D, Sarrazin M, Briand C, Rodriquez A, Nieto JM,
Andreu JM: Interaction of tubulin and cellular microtubules
with the new antitumor drug MDL 27048. A powerful and
reversible microtubule inhibitor.  J Biol Chem 1989,
264:21296-21301.
49. Carre M, Carles G, Andre N, Douillard S, Ciccolini J, Briand C, Bra-
guer D: Involvement of microtubules and mitochondria in the
antagonism of arsenic trioxide on paclitaxel-induced
apoptosis. Biochem Pharmacol 2002, 63:1831-1842.
50. Esquieu D, Peloponese JM, Opi S, Gregoire C, de Mareuil J, Dunot JP,
Sturgis J, Witvrouw M, Pannecouque C, De Clercq E, MontembaultPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Retrovirology 2005, 2:5 http://www.retrovirology.com/content/2/1/5
Page 11 of 11
(page number not for citation purposes)
M, Giang VT, Villiéras M, Fargeas V, Lebreton J, Loret EP: Discovery
of a Tat HIV-1 inhibitor Through Computer-Aided Drug
Design. Spectroscopy 2003, 17:639-645.